How to Localize Labels and Instructions for Use for Medical Device Registration in the UAE

Direct answer: Localizing labels and instructions for use (IFU) for UAE medical device registration requires confirming the target country, the device risk class, the applicable regulatory pathway, and the existing documentation base before assessing technical files, quality system evidence, label and IFU requirements, local agent or authorized representative arrangements, clinical evidence, and post-market maintenance obligations. AIMEILI advises companies to complete a documentation gap assessment before formal submission to avoid extended project timelines caused by unclear classification, incomplete dossiers, or undefined authorization arrangements. For Chinese medical device manufacturers, the more reliable approach is to determine product classification and complete a documentation gap assessment first, then decide whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused.

Published: 2026-07-11 13:53  |  Updated: 2026-07-11 13:53

This FAQ addresses the questions companies most often need to resolve first in international medical device registration, documentation preparation, compliance pathways, and post-market maintenance.

Key Summary

UAE registration typically affects technical files, authorized representation, importer coordination, label language, quality system evidence, and subsequent change maintenance at the same time. If a company only works through the question of "which documents must be submitted," it is likely to encounter deficiencies or rework in model coverage, evidence chain consistency, label claims, and certificate control.

AIMEILI recommends that companies position this question within a broader GHWP member state and multi-country market access strategy, using one reusable core technical file set to support localization across different markets, rather than rebuilding documentation on an ad hoc basis for each country.

Applicable Scenarios and Core Questions

Companies searching for guidance on how to localize labels and IFUs for UAE medical device registration are usually not looking for a conceptual explanation. They need to determine whether existing documentation can support a UAE submission, whether a local agent or authorized representative is required, why timelines are being extended, and which issues may affect launch plans. The question typically involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities at the same time.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America simultaneously, answering the process for a single country is not sufficient. A more valuable approach is to first develop reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence, and label and IFU documentation, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the intended use, mechanism of action, clinical setting, mode of body contact, duration of use, sterility, whether the device is powered, and whether it contains software or has IVD attributes, and then determine the risk class and submission pathway. Once the pathway judgment is wrong, subsequent translation, notarization, authorization, testing, and supplementary submissions will all deviate from the correct direction.

For a UAE project, it is also necessary to confirm the applicant entity and the boundaries of local responsibility: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market incidents, who triggers changes, and who maintains renewal documentation. If these issues are only addressed vaguely in commercial contracts, market control can easily be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management documents, clinical evaluation or clinical evidence, labels and IFUs, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance documentation.

The key to documentation quality is not quantity but consistency. IFU claims, the models covered by test reports, the scope of application of clinical evidence, risk management conclusions, label warnings, and information in the registration application form must all support one another. What regulators assess is whether the device is safe, effective, and traceable for its intended use, not how many documents have been uploaded.

Common Mistakes

The most common problem is treating a registration project as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Submitting directly translated domestic NMPA documentation without reorganizing the evidence according to the UAE pathway.
• Including too many models and specifications while test reports, clinical evidence, or labels do not provide sufficient coverage.
• Selecting a local agent solely on the basis of sales cooperation, without clarifying regulatory responsibilities, certificate control, and post-market maintenance obligations.
• Inconsistency between labels, IFUs, promotional materials, and registration dossier claims, leading to deficiency letters or post-market compliance risks.
• Failing to plan for multi-country documentation reuse in advance, resulting in duplicated preparation for each country and inflated costs and timelines.

Company Preparation Checklist

Before starting a project, companies are advised to use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA, or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management documentation, clinical evaluation, and English IFUs.
• Confirm the responsibilities, fees, certificate control, and exit mechanisms of the local agent or authorized representative.
• Establish a target-country gap assessment table specifying what must be retested, translated, notarized, or supported by additional declarations.

AIMEILI Perspective

AIMEILI advises companies not to view UAE registration as a one-time document submission, but as an overseas market access program to be managed. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it according to national requirements is usually faster, more stable, and more conducive to subsequent changes and certificate renewals than preparing documents on a temporary basis country by country.

From a project management perspective, three things should be controlled in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, the project may still encounter repeated issues during deficiency responses, agent communication, and post-market maintenance, even if the documentation appears extensive.

Frequently Asked Follow-Up Questions

Can domestic Chinese documentation be used directly for UAE registration?

Domestic documentation can serve as a foundation, but it generally cannot be submitted as-is. Companies need to adjust the documentation structure, language, labels, authorization documents, and evidence chain in accordance with local regulatory requirements.

When is the best time to start a gap assessment?

A gap assessment should be started immediately after the target market and product list are confirmed. The earlier the gap assessment is completed, the easier it is to arrange retesting, translation, label adjustments, and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent typically participates in registration communication, changes, renewals, and post-market incident handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project ledger that manages the product list, model and specification data, registration pathway, document owners, translation status, testing status, local agent communication records, and expected submission dates in a single table. This makes it possible to identify documentation gaps promptly and helps management determine whether the project will affect launch plans.

For companies that already have registrations in multiple countries, an evidence reuse matrix should also be established, specifying which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. Labels and IFUs, clinical evaluation, risk management, performance verification, and quality system certificates in particular must be kept version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate control.
• Track translation, notarization, testing, and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators typically assess whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards, and technical file are consistent. If the scope covered by the ISO 13485 certificate does not match the device being submitted, or if the manufacturing address, model and specification data, or IFU version is inconsistent with the test report, the company may be required to provide supplementary explanations even if it has prepared a large number of documents.

Companies should establish an evidence consistency checklist before submission, mapping the product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and IFU version, and quality system certificate item by item. Although this appears to be a basic step, it can significantly reduce the probability of deficiency letters, particularly for projects involving simultaneous submissions in multiple GHWP member states or multiple product families.

Localization Conversion and Agent Responsibilities

UAE registration projects typically involve arrangements with a local agent, authorized representative, importer, or registration holder. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also handles regulatory communication, certificate maintenance, post-market incident reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, IFUs, and authorization documents also cannot simply be translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already hold CE, FDA, NMPA, or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Completing registration does not mean the compliance work is finished. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest substantial effort in obtaining certificates but neglect post-market maintenance; when a manufacturing site change, model expansion, IFU update, or agent replacement occurs later, the certificate and market sales can easily become disconnected.

AIMEILI recommends that companies incorporate this issue into annual international registration planning: first clarify target market priorities, then establish a reusable documentation package and a national gap list, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value of this approach is not only improved registration efficiency in a single country, but also the development of a replicable compliance capability for overseas expansion, reducing the cost of preparing documentation from scratch each time a new market is entered.

Continue Reading

• Previous: How should technical files be organized for medical device registration in the UAE?
• Next: How should clinical evaluation documentation be prepared for medical device registration in the UAE?
• Recommended: What are the risk management documentation requirements for medical device registration in the Philippines?
• Recommended: How should performance verification documentation be prepared for medical device registration in the Philippines?
• Recommended: What should be done when quality system evidence is inconsistent for medical device registration in the Philippines?
• Recommended: How should registration documentation be prepared for medical device registration in Singapore?
• Recommended: How should product classification be determined for medical device registration in Singapore?
• Recommended: How should technical files be organized for medical device registration in Singapore?

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory authorities, international organizations, standards bodies, and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Scope of application: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the official requirements of the target country's regulatory authority, testing conclusions, or legal advice.